Remove Biobanking Remove Clinical Trials Remove Genome Remove Life Science
article thumbnail

The post-Covid New Normal: a golden opportunity for the NHS?

pharmaphorum

I recently had the pleasure of attending the PING Conference 2022 , which had the tagline of ‘The Golden Age for Life Sciences Innovation’. Aspirations for the UK in life sciences. So, with all that said, are we really in a golden age for UK life sciences? Reducing complexity across the NHS.

article thumbnail

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

BAY 2927088 is a reversible small molecule inhibitor that is currently being evaluated in a first-in-human, Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with mutations in epidermal growth factor receptors (EGFR & HER2) including exon20 insertions and point mutations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Generation of strong research dataset cohorts must begin with high-quality clinical samples. Partnerships and Establishing Research Cohorts.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. There are different subtypes of heart failure that have different clinical presentations.”. Heart failure affects about 6.2